Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

PAVmed (PAVM) Shares Outstanding (2016 - 2025)

PAVmed has reported Shares Outstanding over the past 6 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 8.25% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 8.25%, while the annual FY2025 figure was $1.5 million, 8.25% up from the prior year.
  • Shares Outstanding for Q4 2025 was $1.5 million at PAVmed, down from $23.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $92.2 million in Q3 2022 and troughed at $20335.0 in Q2 2025.
  • A 5-year average of $21.7 million and a median of $1.5 million in 2025 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: plummeted 98.61% in 2023 and later soared 1383.27% in 2025.
  • Year by year, Shares Outstanding stood at $5.8 million in 2021, then increased by 9.43% to $6.3 million in 2022, then tumbled by 79.28% to $1.3 million in 2023, then grew by 8.25% to $1.4 million in 2024, then grew by 8.25% to $1.5 million in 2025.
  • Business Quant data shows Shares Outstanding for PAVM at $1.5 million in Q4 2025, $23.1 million in Q3 2025, and $20.1 million in Q2 2025.